| Literature DB >> 12954047 |
J Scott Sawyer1, Bryan D Anderson, Douglas W Beight, Robert M Campbell, Michael L Jones, David K Herron, John W Lampe, Jefferson R McCowan, William T McMillen, Nicholas Mort, Stephen Parsons, Edward C R Smith, Michal Vieth, Leonard C Weir, Lei Yan, Faming Zhang, Jonathan M Yingling.
Abstract
Pyrazole-based inhibitors of the transforming growth factor-beta type I receptor kinase domain (TbetaR-I) are described. Examination of the SAR in both enzyme- and cell-based in vitro assays resulted in the emergence of two subseries featuring differing selectivity versus p38 MAP kinase. A common binding mode at the active site has been established by successful cocrystallization and X-ray analysis of potent inhibitors with the TbetaR-I receptor kinase domain.Entities:
Mesh：
Substances：
Year: 2003 PMID： 12954047 DOI： 10.1021/jm0205705
Source DB: PubMed Journal: J Med Chem ISSN： 0022-2623 Impact factor: 7.446